SOR is backing Australian SMEs with patient capital, incubating deep-tech ventures across AI, energy and critical minerals to ...

Microsoft 365 pricing update 2026 impacts costs, AI features, and licensing. Businesses must review plans to reduce costs and maximise efficiency. MELBOURNE, VICTORIA ...

The Australian government has struck a major five-year volume sourcing agreement with Microsoft to speed up adoption of artificial intelligence (AI) and cloud technologies across the public sector.

In September last year, I wrote about how updating the technology governments use in their operations can help improve service delivery, make room for new services which respond to changing community ...

Carlos Alcaraz became the youngest man ever to complete a career grand slam on Sunday, adding the Australian Open title to his trophy cabinet after defeating Novak Djokovic in an enthralling men’s ...

Elena Rybakina finally won her second Grand Slam title after a 6-4, 4-6, 6-4 victory over top-ranked Aryna Sabalenka at the women's Australian Open final on Saturday, avenging her loss in the ...

Over the past few months, a large-scale cloud storage subscription scam campaign has been targeting users worldwide with repeated emails falsely warning recipients that their photos, files, and ...

Australian neocloud Sharon AI is set to significantly expand its use of Cisco's networking technology following an investment from Digital Alpha. The deal gives Sharon AI access to Digital Alpha's ...

RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they’ll focus now on Casdatifan (AB521), ...

At least 15 people were killed at a beach in Sydney, Australia, on Sunday when a father and son opened fire on a crowd celebrating the beginning of Hanukkah. At least 42 people were hospitalized.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...